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Introduction: Parathyroidectomy (PTx) is recommended in patients affected by secondary hyperpara-
thyroidism (2HPT) of chronic kidney disease-mineral bone disorders (CKD-MBD), resistant to medical
treatment. Analyzing total parathyroidectomy with muscular or subcutaneous autoimplantation (TPai)
outcomes in hemodialysis (HD) 2HPT patients, and monitoring intact parathyroid hormone (iPTH) levels,
we evaluated long-term functional results of subcutaneous parathyroid glandular tissue
autoimplantation.
Methods: 40 HD 2HPT patients, resistant to medical treatment, and awaiting for renal transplantation,
underwent total parathyroidectomy with subcutaneous autoimplantation of 9e12 fragments of not
nodularhyperplasia parathyroid tissue innotdominant forearm. iPTHwere analyzed24h, and 3e6e12e24
months after surgery. The 1.08e6.99 pmol/L range was taken as reference of normal iPTH level based on
which eu- (1.08e6.99), hypo- (<1.08), aparathyroidism (0) and persistence or relapse (>6.99) of disease
were determined.
Results: In every case PTai determined an extraordinary improvement of quality of life, associated with a
notable reduction of iPTH serum level. Immediate normalization of iPTH was achieved in 50% of cases;
hypoparathyroidism in 25% of cases and persistence of disease in 25% were observed. Long term follow-
up showed a reduction of hypoparathyroidism and an increase of relapse rate up to 20%. Grafting
resection was never performed.
Discussion: Subcutaneous autotrasplantation is a very simple and fast surgical technique. Nevertheless,
similar success and recurrence rates were reported following muscular or subcutaneous grafting, as
conﬁrmed in our experience.
Conclusions: Subcutaneous grafting was effective as muscular implantation, with comparable functional
results, but avoiding its potential complications.
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f of Surgical Associates Ltd.1. Summary
Analyzing total parathyroidectomy with muscular or subcu-
taneous autoimplantation (TPai) outcomes in hemodialysis (HD)
2HPT patients, and monitoring intact parathyroid hormone (iPTH)
levels, we evaluated long-term functional results of subcutaneous
parathyroid glandular tissue autoimplantation. 40 HD 2HPT pa-
tients, resistant to medical treatment, and awaiting for renal
transplantation, underwent total parathyroidectomy with
G. Conzo et al. / International Journal of Surgery 12 (2014) S165eS169S166subcutaneous autoimplantation of 9e12 fragments of not nodular
hyperplasia parathyroid tissue in not dominant forearm. In every
case PTai determined an extraordinary improvement of quality of
life, associated with a notable reduction of iPTH serum level. Long
term follow-up showed a reduction of hypoparathyroidism and an
increase of relapse rate up to 20%. Subcutaneous grafting was
effective as muscular implantation, with comparable functional
results, but avoiding its potential complications.
2. Introduction
Incidence of secondary hyperparathyroidism (2HPT) of chronic
Kidney disease-mineral bone disorders (CKD-MBD) increases with
dialysis vintage, and, prior the calcimimetic era, parathyroidectomy
(PTx) became necessary in 15% of cases after 10 years, which raised
to 38% after 20 years [1]. It induces a higher mortality rate partic-
ularly due to irreversible cardiovascular complications and also
anemia, becomes a risk factor for unfavourable cardiovascular
outcomes [2,3]. Therefore, in 2HPT patients, resistant to medical
treatment, early surgery could offer an improved quality of life and
possibly a higher long-term survival rate. Successful surgical
treatment often results in a dramatic reduction of iPTH levels
relieving the patient from clinical symptoms [4e7], and different
papers showed that PTx can also improve mortality and cardio-
vascular morbidity [8e13]. In the surgical management of 2HPT
several techniques have been proposed. Total PTx (TP) without
implantation was in the past reserved to patients not candidates to
renal transplantation, while subtotal PTx (sTP) and total PTx with
muscular or subcutaneous autoimplantation, preserving a small
amount of abnormal parathyroid tissue, are the most common
procedures. Implantation was proposed in different sites: neck,
forearm, abdomen, pre-sternum [14e17]. In the preoperative
evaluation of the most efﬁcacious technique, grafting failure,
recurrence and technical difﬁculties associatedwith reintervention,
must be considered. In case of 2HPT recurrence, to avoid the
complications associated with resection of muscular hypertrophied
grafts, subcutaneous implantationwas introduced. Different papers
demonstrated that subcutaneous technique could be effective as
muscular grafting, but with less morbidity [18,19]. We evaluated
long-term functional results of subcutaneous parathyroid glandular
tissue autoimplantations, and, reviewing TPai literature, we
compared subcutaneous and muscular autoimplantation published
data.
3. Study design
A retrospective analytical cohort study, in a group of 40 HD
patients with severe 2 HPT, unresponsive to medical treatment,
awaiting for renal transplantation, addressed to our Institution
from regional HD centres, and selected for PTai, was performed.
iPTH levels >53e84 pmol/L, serum P level >6.5 mg/100 mL, US
enlarged parathyroid glands (>1 cm or >500 mm3) and persisting
clinical symptoms, six months after medical therapy, were
considered the main criteria for PTai. Cardiovascular disease was
deﬁned as presence of hypertension, peripheral artery disease, ECG
signs of cardiac hypertrophy, US cardiac valves calciﬁcation, ven-
tricular hypertrophy, arrhythmia, coronary or cerebrovascular dis-
ease. Anemia was evaluated according to the Royal College of
Physicians (UK) National Clinical Guideline Centre [20]. Ptx was
considered successful when postoperative iPTH level was
<26.52 pmol/L. The 1.08e6.99 pmol/L range was taken as reference
of normal iPTH level based onwhich eu- (1.08e6.99), hypo- (<1.08),
aparathyroidism (0) and persistence or relapse (>6.99) of disease
were determined. Hypocalcemia was considered to be present
when serum calcium was <1.99 mmol/L (normalvalue ¼ 2.10e2.55 mmol/L).During 24 months follow-up, surgical
outcomes, survival and functional results of the autoimplantations
were evaluated.
4. Methods
Data were retrospectively collected from 40 consecutive pa-
tients (14_ and 26 \), affected by 2HPT of CKD-MBD, on standard
three-weekly HD, and submitted to PTai between January 2006 and
January 2008. All patients gave informed consent to participate in
the study. Preoperative medical treatment consisted in phosphate
chelators (Ca carbonate, sevelamer, lanthanum carbonate), dialysis
baths with various Ca concentrations, vitamin D and its analogues.
The ESA treatment regimen consisted in three-weekly recombinant
human ESA (alfa-erythropoietin) injections - 5.200 ± 3824.48 IU, in
38/40 patients. 2/40 patients was treated with alfa darbepoetin 30
(30 mg/every 15 days).
High-resolution neck ultrasonography, ENT examination, tech-
netium- 99m-sestamibi scintigraphy of the neck and mediastinum,
were the main preoperative diagnostic procedures. 12-lead ECG
and epiaortic 2-dimensional and color doppler transthoracic
echocardiogram, by experienced in center cardiologists, and pe-
ripheral artery color doppler ultrasonography examination were
pre and postoperatively performed. iPTH, Ca, P, alkaline phospha-
tase (ALP) and FT3, FT4, TSH, thyroglobulin were measured along
with ﬁne needle biopsy of the thyroid nodules; to minimize the
dilution effect on laboratory assays, all blood samples were ob-
tained before dialysis. The LiaisonⓇNTactⓇPTH Assay (DiaSorin
Inc-Stillwater, MN, USA), based on chemiluminescence immuno-
assay (CLIA), was used for the quantitative determination of iPTH
(Coefﬁcient of variation: CV% intra assay 1.7e3.7; CV% inter assay
2.6e5.9; limit of detection 0.07 pmol/L). Indications to surgical
procedure were set according to both K/DOQI 2003 guidelines and
Y Tominaga et al. [10,15] Regarding the surgical procedures, pa-
tients underwent total parathyroidectomy with auto-
transplantation (TPai) of 9e15 fragments of non-nodular glandular
tissue, in 3 subcutaneous pockets of the non-dominant forearm. In
22 out of 40 patients (55%) with thyroid gland disease, 16 total
thyroidectomy and 6 hemithyroidectomy procedures were per-
formed. In all cases, 4 parathyroid glands at least were removed
(the nature of the tissue was conﬁrmed via intraoperative histo-
logical examination). Only in a few cases, a HD treatment was
required immediately after surgery, due to an electrolyte imbal-
ance. The majority of patients required intravenous administration
of calcium, due to postoperative hypocalcemia. Patients completed
long-term follow-up monitoring of iPTH from the implantation site
and from the contralateral arm, in order to evaluate the gradients.
5. Results
5.1. Demographics
Patient mean agewas 52 years (range 25e72), andmean dialysis
vintage was 96 months (1e28 years). Mean preoperative iPTH was
165.79 pmol/l (range 82.66e495.16), andmean serum calcium level
was 2.37 mmol/l (range 2.18e2.91) (Table 1). All patients reported
diffuse pruritus, arthromyalgia and mood alterations, while the
incidence of baseline cardiovascular pathologies is reported in
Table 2. No case of calciphylaxis was reported. 22 patients (55%)
suffered from coexisting thyroid pathology. None of them had iron
deﬁciency or external blood loss and a mild or moderate anemia
(Hb level 7 e <12 gr/dl) was observed. Preoperative instrumental
tests (both cervical ultrasound and sestamibi scintigraphy) were
not useful in identifying supernumerary glands, that is the exact
number of glands or their precise location [21].
Table 3
Postoperative results (%).
Eupara Hypopara Pers. Relapse
One day 50 25 25 e
One year 40 5 25 20
Two years 40 5 25 20
Euparathyroidism ¼ PTH 1.08e6.99 pmol/L.
Hypoparathyroidism ¼ PTH <1.06 pmol/L.
Persistence ¼ PTH > 6.89 pmol/L before six months of follow-up.
Relapse ¼ PTH > 6.89 pmol/L six months after surgery.
Postoperative results relative to percentage of patients in Eupara, Hypopara,
Persistence or Relapse (one day, one and two years after surgery).
Table 1
Preoperative data.
Pz Ca iPTH P Ca  P AP
1 2.4 82.66 6.8 65.28 147
2 2.35 152.85 3.7 34.78 1226
3 2.38 166.31 2.5 23.75 332
4 2.18 109.83 6.2 53.94 250
5 2.43 199.57 4.5 43.65 146
6 2.20 108.72 6.6 58.08 150
7 2.25 188.37 5 45 82
8 2.33 178.47 5.6 52.08 356
9 2.38 208.83 6.2 58.9 454
10 2.35 118.41 6.4 60.16 208
11 2.90 146.29 7.3 84.68 254
12 2.45 181.38 10.5 102.9 146
13 2.35 192.84 4.4 41.36 318
14 2.48 83.96 5.3 52.47 170
15 2.20 139.94 4.3 37.84 204
16 2.38 99.03 7.3 69.35 226
17 2.38 158.56 4.1 38.95 552
18 2.33 495.16 4.6 42.78 1040
19 2.30 171.15 4.5 41.4 310
20 2.38 116.15 8.4 79.8 511
21 2.39 83.68 6.7 64.24 140
22 2.35 150.79 3.9 36.70 1130
23 2.38 170.48 2.8 28.65 342
24 2.36 109.47 6.0 51.94 238
25 2.30 175.66 4.8 41.4 305
26 2.44 182.34 10.1 103 140
27 2.91 146.29 7.7 86.84 264
28 2.23 188.50 4.8 55.60 101
29 2.21 143.84 4.2 39.35 209
30 2.32 386.19 5.3 42.47 1003
31 2.42 184.14 6.1 70.63 156
32 2.28 117.71 3.9 41.4 312
33 2.37 173.51 8.6 69.4 523
34 2.25 190.34 5.2 49.8 119
35 2.31 174.46 4.9 43.7 322
36 2.36 108.13 4.2 45.6 280
37 2.64 140.80 8.1 93.1 275
38 2.23 143.88 4.7 40.2 220
39 2.31 179.70 5.0 48.3 318
40 2.37 183.34 6.3 66.71 149
Ca ¼ Calcium (n.v. ¼ 2.10e2.55 mmol/l).
P ¼ Phosphate (n.v. ¼ 2.7e4.5 mg/dl).
iPTH ¼ Intact Parathyroid Hormone (n.v. ¼ 1.08e6.99 pmol/L).
AP ¼ Alkaline Phosphatase (n.v. ¼ 53e128 U/L).
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Surgical treatment produced a beneﬁt in terms of itching, a
substantial improvement in clinical osteoarticular symptoms as
well as in mood patterns ﬁrst, and later in sleep disorders, an in-
crease in muscular strength, which were associated to a statistically
signiﬁcant reduction in PTH levels both immediately and after one
year, ESA need and improvement of Hb levels. All patients displayed
a dramatic reduction in intraoperative iPTH levels, even after the
removal of only two monolateral parathyroid glands. No signiﬁcant
peri- or postoperative complications were observed. None of the
patients was found to be aparathyroid (Tables 3). Twenty-fourTable 2
Incidence of base-line cardiovascular pathologies (%).
Hypertension 55.0
Coronary disease 3.3
Myocardial infarction 5.0
Cardiac arrhytmias 10.0
Peripheral vascular disease 15.0
Cardiac valve calciﬁcation 10.0patients (60%) required intravenous postoperative administration
of calcium gluconate due to hypocalcemia, which was occasionally
severe, with a minimum value of 1.42 mmol/L, but was never
associated with hypocalcemic seizures. The deﬁnitive histological
examination conﬁrmed the hyperplasia of the removed glands; 4
patients (10%) had 5 hyperplastic glands; 16 patients (40%) had an
associated multinodular goiter, 4 (10%) an adenomatous goiter and
2 (5%) papillary carcinoma. Table 3 shows immediate (on post-
operative day 1) and long term TPai functional results. In one pa-
tient, with an immediate iPTH normalisation after surgery, the 6-
month follow up revealed a mean systemic iPTH level of
103.88 pmol/L compared to the cubital fossa of the forearm trans-
plantation site measurement where the iPTH was 169.6 pmol/L. In
this patient, the transplanted glandular tissue was removed under
locoregional anaesthesia, and the histological examination showed
non-hyperplastic parathyroid tissue. After 12 months, the iPTH
level was 161.23 pmol/L, and a whole body technetium 99m ses-
tamibi scintigraphy showed areas of mediastinic tracer uptake
adjacent to the heart (which was not present at the earlier sesta-
mibi scintigraphy). The patient refused reintervention.
After one year Computed Bone Mineralometry and skeletal X-
rays showed a clear regression of osteodystrophy in all patients,
irrespective of the procedure carried out. 12/40 patients (30%),
successfully underwent renal transplantation. No long-term path-
ological fractures were reported. The overall mortality rate one year
after surgical treatment was 10% (4/40 cases) (1 rupture of
abdominal aortic aneurysm, 3 heart failure).6. Discussion
Standard medical treatment of 2HPT of CKD consists of phos-
phate chelators (Ca carbonate, sevelamer, lanthanum carbonate),
dialysis baths with various Ca concentrations, vitamin D and its
analogues, and calcimimetics, marketed in 2004. The latter acts on
the Ca sensing receptors in the primary cells of parathyroid glands,
inhibiting glandular hyperplasia, and reducing signiﬁcantly the
circulating PTH levels [22,23]. Their recent diffusion will certainly
have a major impact on 2HTP management, reducing the in-
dications to surgical procedures. Regarding surgical indications,
KDIGO parameters modiﬁed the National Kidney Foundation (NKF)
guidelines, by referring to local normal laboratory ranges for Ca,
phosphorus and for PTH levels between 2 and 9 times the normal
range [2]. 2HPT may increase mortality rate in the HD population,
particularly by irreversible cardiovascular complications [24].
Pathological modiﬁcations of mineral metabolism, phosphates over
all, worsening atherosclerosis symptoms and favouring arterial
stiffness, increase the risk of cardiovascular morbidity and mor-
tality. Therefore, in patients unresponsive to medical treatment,
early surgery could offer an improved quality of life and possibly a
higher long-term survival rate with a morbidity rate similar to that
reported in thyroid surgery [25e27]. Dramatic reduction of iPTH
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of haematocrit and of Hb levels and, probably, a signiﬁcant decrease
of ESA requirement, in most operated patients [28], could explain
the beneﬁcial effects of parathyroidectomy. Different studies
showed that PTx can also improve mortality and cardiovascular
morbidity [8e11]. Considering the surgical technique, the removal
of at least 4 glands provides excellent results in terms of clinical and
laboratory parameters [22,29]. Nevertheless, the presence of su-
pernumerary glands (10% of HD population) could negatively in-
ﬂuence surgical results, causing sometimes a relapse, determined
less frequently either by hypertrophy of the autotransplantation, or
of the cervical glandular fragment. "Iatrogenic" parathyromatosis
or hyperplasia of residual cell nests are a less frequent causes of
relapse. At present, the rapid intraoperative assay of iPTH allows a
substantial improvement in the diagnostic accuracy, and we
strongly suggest that it should be considered as a procedure of
choice [30,31]. In patients awaiting renal transplantation, sTP and
TP plus muscular or subcutaneous grafting are the most popular
procedures, while TP, without tissue implantation, is reserved in
patients not awaiting transplant. Nevertheless, they are character-
ized by a long-term risk of relapse (10% of cases), leading to a higher
morbidity, since it requires further diagnostic and therapeutic in-
terventions (surgery, percutaneous alcoholisation). KDOQI guide-
lines conﬁrm the efﬁcacy of different operations, indicating that the
selection criteria of the procedure of choice depend on preference
and experience of each surgeon [32]. Nevertheless, as demon-
strated in different reports, the feared aparathyroidism following
TP seems to be a "virtual" result. In fact H. Dralle afﬁrms that in
2HPT it is extremely difﬁcult to completely abolish parathyroid
function [33]. N. Rayes, examining 8 studies involving 147 patients
who underwent TP between 1989 and 2006, revealed measurable
PTH in the majority of patients, occasionally at higher than normal
concentration. TP did not cause symptomatic hypocalcaemia, nor
the onset of adynamic bone disease. The rate of relapse in 6 out of 8
studies varied between 8 and 35% [34]. Analysis of literature con-
ﬁrms that TP is a safe procedure, allowing a high postoperative
success rate also in patients with a more advanced dialytic vintage
and a more aggressive 2HPT. In patients awaiting transplantation,
sTP and TP plus muscular or subcutaneous autotransplantation are
the most widespread procedures, with the aim of restoring
euparathyroidism preserving a certain amount of residual tissue.
These procedures are characterised by effective results, but also by
a risk of long-term relapse, which occurs in around 10% of cases. In
2HPT patients, persisting chronic renal failure after surgery, the
glandular autoimplantation will be continuously stimulated with
a high risk of recurrence. In case of muscular grafting local recur-
rence, a broad muscular excision may be required, signiﬁcantly
improving the morbidity of the reintervention, especially for neck
implantation. To avoid these complications, many authors
preferred subcutaneous grafting [18], retaining that subcutaneous
tissue is a favourable environment for parathyroid cells.
Moreover subcutaneous autotrasplantation is a very simple and
fast surgical technique. Nevertheless, similar success and recur-
rence rates were reported following muscular or subcutaneous
grafting, as conﬁrmed in our experience. According to previously
reported data, the adipose tissue is useful for the function of grafted
parathyroid tissue fragments, and, moreover, the forearm, allowing
the iPTH gradient evaluation, is preferable. Aparthyroidism was
never observed in our series, but we couldn’t exclude in every case
the presence of a supernumerary gland, or ectopic parathyroid
tissue as responsible of iPTH secretion. The main limit of this
retrospective analysis was the small number of examined patients.
Considering the success rate of subcutaneous implantation, simple
and fast surgical procedure, we suggest its use in the treatment of
2HPT.Ethical approval
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